Lecanemab, a monoclonal antibody treatment marketed under the brand name Leqembi, represents a significant milestone in the clinical management of…
Read More
Scientists Uncover the Cellular Mechanism of Lecanemab in Alzheimer’s Disease and the Critical Role of the Fc Fragment in Plaque Clearance
The quest to understand and treat Alzheimer’s disease has reached a significant milestone as researchers from VIB and KU Leuven…
Read More
Unlocking the Mechanism of Lecanemab: VIB-KU Leuven Researchers Identify Fc Fragment as Essential for Microglial Activation in Alzheimer’s Treatment
Researchers from the VIB-KU Leuven Center for Brain & Disease Research have published a seminal study in the journal Nature…
Read More
